US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Alcobra

10.22

0.0000

Volume:- -

Turnover:- -

Market Cap:281.69M

PE:-11.48

High:10.22

Open:10.22

Low:10.22

Close:10.22

52wk High:18.04

52wk Low:5.81

Shares:27.56M

Float Shares:8.88M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8900

ROE:--

ROA:--

PB:5.96

PE(LYR):- -

Loading ...

Overview Company News Filings

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control

In My Forties I Found Out I Have ADHD -- Maybe You Do Too -- WSJ

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

Luo Yonghao Discloses ADHD Diagnosis: May Cease Large-Scale Events if Medication Change Fails or Physical Condition Issues Persist

Grant Cardone Says ADHD Isn't A Disorder But 'Misunderstood Genius' — It's A 'Gift From God' That Helps People Chase Multiple Passions

China Resources Double-Crane Pharmaceutical's ADHD Capsules Included in China's Insurance Catalog

MT Newswires Live

Investment Legend Charlie Munger's Final Chapter Revealed: Unconventional Choices

When ADHD Meds Are Just the Start -- WSJ

For Kids, ADHD Pills Are Often Just the Start -- WSJ

Millions of Kids Are on ADHD Pills. For Many, It's the Start of a Drug Cascade. -- WSJ

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report

ADHD Startup's Founder Is Found Guilty of Conspiracy in Adderall Case -- WSJ

Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute

Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

Press Release: Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Supernus Announces Third Quarter 2025 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ADHD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADHD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","market":"US","secType":"STK","nameCN":"Alcobra","latestPrice":10.22,"timestamp":1510952400000,"preClose":10.22,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":8881019,"shares":27563000,"eps":-0.89,"marketStatus":"Delisted","change":0,"latestTime":"02-12 14:19:44 EST","open":10.22,"high":10.22,"low":10.22,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.89,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.22,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","floatShares":8881019,"roa":"--","roe":"--","lyrEps":0,"shares":27563000,"dividePrice":0,"high":10.22,"amplitude":0,"preClose":10.22,"low":10.22,"week52Low":5.8113,"pbRate":"5.96","week52High":18.0414,"institutionHeld":0,"latestPrice":10.22,"eps":-0.89,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.89,"open":10.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADHD\",params:#limit:5,,,undefined,":[{"date":"2017-11-16","symbol":"ADHD","newSymbol":"ARCT","type":"symbolChange","dateTimestamp":1510808400000},{"date":"2017-11-15","symbol":"ADHD","type":"split","dateTimestamp":1510722000000,"forFactor":7,"toFactor":1},{"market":"US","date":"2017-11-09","symbol":"ADHD","fiscalQuarterEnding":"2017/09","expectedEps":-0.08,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2017-08-11","symbol":"ADHD","fiscalQuarterEnding":"2017/06","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1502424000000,"reportTimeType":"","actualEps":-0.13},{"market":"US","date":"2017-05-30","symbol":"ADHD","fiscalQuarterEnding":"2017/03","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1496116800000,"reportTimeType":"","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADHD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADHD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADHD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608386286","title":"Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2608386286","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608386286?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:45","pubTimestamp":1770039900,"startTime":"0","endTime":"0","summary":"Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation TechniquesHOUSTON, TX, Feb.  0","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/02/3230298/0/en/Nexalin-Highlights-its-Expanding-Body-of-Peer-Reviewed-Neuroimaging-Research-Confirming-its-DIFS-Technology-as-the-Leader-in-Evidenced-Based-Non-Invasive-Brain-Stimulation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4120","LU2308191902.HKD","ADHD","IE00B7SZL793.SGD","MEG"],"gpt_icon":0},{"id":"2607303354","title":"Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2607303354","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607303354?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:11","pubTimestamp":1769695893,"startTime":"0","endTime":"0","summary":"Takeda missed Q3 earnings estimates as Vyvanse generic pressure weighed on sales, but raised its 2025 profit forecast on cost discipline and favorable currency moves.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/01/50229026/takeda-flags-vyvanse-hit-lifts-2025-profit-guidance-on-cost-control","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1003077747.HKD","CMS","BK4588","LU2637428348.USD","TAK","LU0661504455.SGD","LU0553294199.USD","LU0949170772.SGD","LU2500361329.USD","LU0738911758.USD","ADHD","BK4208","LU1894683264.USD","LU1894683348.USD","LU2346227817.USD","BK4007","BK4585","LU0545039389.USD"],"gpt_icon":0},{"id":"2605496400","title":"In My Forties I Found Out I Have ADHD -- Maybe You Do Too -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2605496400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605496400?lang=en_us&edition=fundamental","pubTime":"2026-01-24 04:00","pubTimestamp":1769198400,"startTime":"0","endTime":"0","summary":"Are you, or is someone you know, \"so ADD\"?Welcome to the club. I don't actually endorse membership. I say this as someone who learned a year ago, in my forties, that I have ADHD .Actual statistics on ADHD are indeed pretty staggering: a 2024 survey found that 25% of adults suspect they have it. The fastest growing cohort being diagnosed is adult women. From 2020 to 2022, the diagnosis rate nearly doubled among women aged 23 to 49.Are Instagram algorithms poisoning the masses by rattling off symptoms associated with ADHD that most people have to some extent -- like having a hard time motivating to do laundry?Social media is one of the most commonly used sources for mental health information. Posts about ADHD on TikTok have been viewed somewhere in the neighborhood of 28 billion times .I'd noticed the impact of technology on my attention but I'd always thought of myself as overly focused, fixated on things even. I once stayed up until 2 a.m. reading Ted Kennedy's testimony about what hap","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADHD","ABVC"],"gpt_icon":0},{"id":"2603457600","title":"Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603457600","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603457600?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:00","pubTimestamp":1768482000,"startTime":"0","endTime":"0","summary":"STOUGHTON, Mass., Jan.  15, 2026  (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/15/3219495/34897/en/Collegium-to-Present-Four-Real-World-Data-Posters-at-APSARD-2026-Annual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","ADHD","BK4588","CII","BK4139","CNS","BK4023","ABVC","BK4585","HCP"],"gpt_icon":0},{"id":"2603612821","title":"Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2603612821","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603612821?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:00","pubTimestamp":1768399200,"startTime":"0","endTime":"0","summary":"Four weeks of non-invasive DIFS neurostimulation delivers meaningful attention gains alongside objective brain imaging changesHOUSTON, TX, Jan.  14, 2026  (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/14/3218706/0/en/Published-Peer-Reviewed-Study-Demonstrates-Nexalin-s-DIFS-Neurostimulation-Improves-Attention-and-Normalizes-Brain-Activity-in-Patients-with-ADHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","LU2308191902.HKD","BK4120","IE00B19Z4B17.USD","MEG","BK4139","ADHD","ABVC","IE00B7SZL793.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2601869041","title":"Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2601869041","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601869041?lang=en_us&edition=fundamental","pubTime":"2026-01-06 14:45","pubTimestamp":1767681900,"startTime":"0","endTime":"0","summary":"Figure 1. Each Azstarys capsule contains 70% SDX and 30% d-MPH . Robust Clinical Data Addresses Unmet Need:In a pivotal Phase III clinical trial in Chinese patients with ADHD, Azstarys met both the primary and key secondary endpoints. The study demonstrated statistically significant and clinically meaningful improvements in core ADHD symptoms compared to placebo at all assessment time points. With limited treatment options in China and historical supply constraints for traditional single-agent therapies, the approval of this innovative combination product offers an important new choice for clinicians and patients.Unique Dual Mechanism for Rapid Onset and All-Day Coverage:Azstarys combines immediate-release and prodrug-based extended-release technologies. Its'rapid onset + full-day coverage'profile positions it to reshape the ADHD treatment paradigm in China. As thefirst ADHD medication in China to deliver both rapid onset and sustained sy","market":"other","thumbnail":"https://mma.prnewswire.com/media/2855260/AK0901_EN.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2855260/AK0901_EN.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ark-biopharmaceutical-receives-china-marketing-authorization-for-azstarys-for-the-treatment-of-adhd-302653543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADHD","SDX.AU","ABVC"],"gpt_icon":0},{"id":"1139437794","title":"Luo Yonghao Discloses ADHD Diagnosis: May Cease Large-Scale Events if Medication Change Fails or Physical Condition Issues Persist","url":"https://stock-news.laohu8.com/highlight/detail?id=1139437794","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139437794?lang=en_us&edition=fundamental","pubTime":"2025-12-31 09:20","pubTimestamp":1767144048,"startTime":"0","endTime":"0","summary":"On December 31, Luo Yonghao revealed in a Weibo post that he has long been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Luo Yonghao stated that due to his ADHD, none of his product...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139","ADHD"],"gpt_icon":0},{"id":"2590953409","title":"Grant Cardone Says ADHD Isn't A Disorder But 'Misunderstood Genius' — It's A 'Gift From God' That Helps People Chase Multiple Passions","url":"https://stock-news.laohu8.com/highlight/detail?id=2590953409","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590953409?lang=en_us&edition=fundamental","pubTime":"2025-12-11 02:01","pubTimestamp":1765389660,"startTime":"0","endTime":"0","summary":"Grant Cardone isn't exactly known for keeping things subtle. The high-octane real estate mogul and motivational speaker has long made headlines with his unapologetically bold takes, and his views on mental health labels are no exception. This time, he's turning ADHD and bipolar disorder on their heads—insisting they're not disorders at all, but misdiagnosed brilliance.In November, Cardone posted a video to his official Facebook page with the caption: \"ADHD is just misunderstood genius.\". In the clip, Cardone appears on camera during an interview, explaining his belief that society pathologizes traits it doesn't understand. \"ADD, ADHD, bipolar—all these manic kind of people—they've been labeled something negative by some fake doctor,\" he said.To be clear, Cardone may wear many hats—investor, author, speaker—but none of them are \"doctor.\" He's not advising anyone to skip their meds or ignore real diagnoses. Many p","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/10/Grant-Cardone--Elena-Lyons-Cardone-At-Th.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/10/Grant-Cardone--Elena-Lyons-Cardone-At-Th.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/topics/25/12/49313663/grant-cardone-says-adhd-isnt-a-disorder-but-misunderstood-genius-its-a-gift-from-god-that-helps-people-chase-multiple-passions","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/topics/25/12/49313663/grant-cardone-says-adhd-isnt-a-disorder-but-misunderstood-genius-its-a-gift-from-god-that-helps-people-chase-multiple-passions","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["CCF","BK4109","ABVC","BK4139","ADHD"],"gpt_icon":0},{"id":"2590318095","title":"China Resources Double-Crane Pharmaceutical's ADHD Capsules Included in China's Insurance Catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318095","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590318095?lang=en_us&edition=fundamental","pubTime":"2025-12-09 15:29","pubTimestamp":1765265362,"startTime":"0","endTime":"0","summary":"Chinese authorities included the dextromethorphan hydrochloride sustained-release capsules manufactured by China Resources Double-Crane Pharmaceutical  subsidiary Henan Zhongshuai Pharmaceutical in the country's national insurance drug catalog.The drug is used as a psychostimulant for attention deficit hyperactivity disorder and nodular disorders in children aged 6 and above, according to a Tuesday filing with the Shanghai bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0010","BK4139","ADHD","BK0188","BK0185","BK0028","600062","BK0175","BK0239","ABVC"],"gpt_icon":0},{"id":"1181205915","title":"Investment Legend Charlie Munger's Final Chapter Revealed: Unconventional Choices","url":"https://stock-news.laohu8.com/highlight/detail?id=1181205915","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181205915?lang=en_us&edition=fundamental","pubTime":"2025-11-27 13:30","pubTimestamp":1764221437,"startTime":"0","endTime":"0","summary":"In the year before his passing, Charlie Munger, Warren Buffett's longtime partner, made surprising investments—including a $50 million profit from an industry he had avoided for six decades—while...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149725797.USD","LU1914381329.SGD","BRK.A","IE000M9KFDE8.USD","LU0640476718.USD","IE00B3S45H60.SGD","IE00BKDWB100.SGD","BRK.B","LU1366333091.USD","LU0234572021.USD","LU1571399168.USD","LU2168564495.EUR","IE00B1XK9C88.USD","BK4588","BK4533","LU0980610538.SGD","IE00BK4W5M84.HKD","LU1201861249.SGD","LU0251142724.SGD","BK4581","IE00BJLML261.HKD","LU0256863811.USD","LU2168564149.EUR","IE00BK4W5L77.USD","LU0787776722.HKD","LU2168563687.JPY","LU0053666078.USD","LU2168564222.USD","LU2168564065.EUR","BK4176","IE00B775SV38.USD","LU0648001328.SGD","LU0210528500.USD","LU0048573561.USD","LU0417517546.SGD","IE00B1BXHZ80.USD","LU0154236417.USD","BK4585","LU0251131958.USD","BK4534","LU0170899867.USD","LU0971096721.USD","IE0034235303.USD","LU2487616109.SGD","LU0157215616.USD","LU0130102774.USD","LU1074936037.SGD","LU1280957306.USD","IE00BWXC8680.SGD","ADHD","LU0683600562.USD","LU1363072403.SGD","BK4550","LU0742534661.SGD","LU0234570918.USD"],"gpt_icon":1},{"id":"2585012982","title":"When ADHD Meds Are Just the Start -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2585012982","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585012982?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:57","pubTimestamp":1763762220,"startTime":"0","endTime":"0","summary":"This is an edition of the WSJ Weekend Reads newsletter, a weekly look at our most colorful, thought-provoking and original feature stories on the business of life. If you're not subscribed, sign up here.Danielle Gansky was 7 years old when she started taking medication for ADHD. By her late 20s, she had taken 14 different kinds of psychiatric pills.Tens of thousands of kids who take prescription ADHD medication like Danielle did also wind up on other powerful psychotropic drugs. This week, we have an in-depth look at this trend of childhood overmedication and its lasting effects.\"I was living in a body hijacked by the medication,\" says Danielle, who at 29 still is struggling to wean herself off an antidepressant.Other topics that we delve into include trans-Atlantic cruises, the new \"Wicked\" movie and the joy of doing nothing in retirement.Enjoy your weekend with these and all the great reads below.Many children who are prescribed medication for ADHD end up taking other powerful psychi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","ADHD","BK4139"],"gpt_icon":0},{"id":"2585141502","title":"For Kids, ADHD Pills Are Often Just the Start -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2585141502","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585141502?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:55","pubTimestamp":1763736900,"startTime":"0","endTime":"0","summary":"This is an edition of the WSJ Health newsletter, a weekly briefing on what's new in health, medicine, personal well-being and the business of healthcare. If you're not subscribed, sign up here.The newsletter won't publish the Friday after Thanksgiving. Your next edition will arrive the following week. Enjoy the break!For many kids, ADHD pills are the start of a drug cascade. The next steps are often powerful psychotropic drugs -- including antipsychotics, antidepressants and sleep aids -- even though their combined effects in young children haven't been studied closely.Separately, the founder of an ADHD startup was found guilty of conspiracy. Ruthia He, whose company Done Global was the subject of a WSJ investigation, was accused of orchestrating a scheme to profit from Adderall prescriptions.Trump administration officials discussed curbing the role of the FDA commissioner, Marty Makary, after complaints about his management style, though the idea was dropped.The FDA called for the rem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADHD","ABVC"],"gpt_icon":0},{"id":"2584034809","title":"Millions of Kids Are on ADHD Pills. For Many, It's the Start of a Drug Cascade. -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2584034809","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584034809?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:00","pubTimestamp":1763604000,"startTime":"0","endTime":"0","summary":"By Shalini Ramachandran,Betsy McKay and Tom McGinty | Design by Audrey Valbuena. Danielle Gansky was 7 years old when an administrator at her upscale private girls' school in suburban Philadelphia flagged problems with her academic performance. She was a bubbly and creative kid, but she was easily distracted in class and her schoolwork was sloppy.More pills followed. Over the years, Gansky was always on two and sometimes three or more psychiatric drugs at once. By her late 20s, she had taken 14 different kinds of psychiatric pills.None of it ever felt right. The pills dulled her mind and made her irritable or sleepy. But when Gansky complained about the drugs, her doctors would up her dose or try another medication.\"I was living in a body hijacked by the medication,\" said Gansky, 29, who is still struggling to wean herself off an antidepressant. \"I didn't have the words or authority to challenge what I was being told.\". The Journal compared about 166,000 children aged 3 to 14 who start","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139","ADHD"],"gpt_icon":0},{"id":"2584929819","title":"Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929819","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929819?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:26","pubTimestamp":1763569560,"startTime":"0","endTime":"0","summary":"A federal jury has convicted Ruthia He, the founder of the telehealth startup Done Global, for orchestrating a scheme that transformed the company into an unrestricted source for Adderall prescriptions. Prosecutors argued that this case highlighted serious abuses in online mental health care, as reported by the Wall Street Journal.Teva Pharmaceutical Industries Ltd  is the largest manufacturer of brand-name and generic Adderall, the most commonly usedto treat attention deficit hyperactivity disorder .In June 2024, Alphabet Inc.'s   Google and TikTok banned Done Global from advertising on their platforms amid a widening federal crackdown on the telehealth company's distribution of Adderall and other stimulants.Jurors concluded that He and Done's former top medical officer, David Brody, conspired to distribute controlled substances to more than 100,000 patients through lax prescribing practices that prioritized growth and revenue.One Done patient later died after receiving an Adderall pr","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/19/Middletown--Ct-Usa---August-7--2023-Adde.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/19/Middletown--Ct-Usa---August-7--2023-Adde.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48954296/jury-convicts-done-global-founder-in-adderall-distribution-scheme-wsj-report","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48954296/jury-convicts-done-global-founder-in-adderall-distribution-scheme-wsj-report","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["IE00BJTD4V19.USD","LU0949170426.SGD","LU0203202063.USD","USJW.SI","LU0648001328.SGD","LU2168564495.EUR","IE00BJJMRX11.SGD","LU0320765489.SGD","LU1032955483.USD","BK4561","LU2463028550.USD","LU2213496289.HKD","LU0456855351.SGD","LU1280957306.USD","LU0312595415.SGD","LU0345768153.USD","LU2756315664.SGD","LU0820561818.USD","LU0965508806.USD","TEVA","IE00BMPRXN33.USD","LU0426417589.USD","LU1196500208.SGD","LU1803068979.SGD","SG9999014914.USD","LU0882574139.USD","LU0417517546.SGD","IE00BZ1G4Q59.USD","LU0310800379.SGD","LU0494093205.USD","LU1037948541.HKD","ABVC","IE0009356076.USD","IE00BFSS8Q28.SGD","LU0957791311.USD","LU0061474705.USD","LU0792757196.USD","LU1815333072.USD","IE0004086264.USD","LU0949170772.SGD","LU1037948897.HKD","IE0001KFT4U8.USD","LU2089283258.USD","LU1221951129.SGD","LU1852331112.SGD","LU1988902786.USD","LU0079474960.USD","ADHD"],"gpt_icon":1},{"id":"2584964162","title":"ADHD Startup's Founder Is Found Guilty of Conspiracy in Adderall Case -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2584964162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584964162?lang=en_us&edition=fundamental","pubTime":"2025-11-19 07:20","pubTimestamp":1763508000,"startTime":"0","endTime":"0","summary":"A jury found Ruthia He guilty of conspiring to distribute controlled substances after her startup Done Global became a ready source of Adderall prescriptions for more than 100,000 patients.The jury found He and Done's former top doctor, David Brody, guilty on two conspiracy counts and four counts of distributing controlled substances. He, Done's former chief executive, was also found guilty of conspiring to obstruct justice. Both defendants could go to prison for decades. Sentencing is scheduled for February.The company was the subject of a series of articles in The Wall Street Journal from 2022 to 2024 describing how some Done clinicians felt pressured to prescribe stimulants such as Adderall, while others wrote prescriptions much faster than is typical for clinicians doing thorough patient evaluations.The company has previously said it is a technology platform that connects patients with medical professionals and doesn't prescribe medications. It has also defended its prescription pr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADHD","ABVC"],"gpt_icon":0},{"id":"2584620065","title":"Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2584620065","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584620065?lang=en_us&edition=fundamental","pubTime":"2025-11-18 00:26","pubTimestamp":1763396760,"startTime":"0","endTime":"0","summary":"Texas judge rejects bid to block Kenvue's $398 million dividend and declines to restrict Tylenol marketing as the company faces a lawsuit over pregnancy safety claims.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/17/Tylenol-safety-issues-for-pregnant-women.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/17/Tylenol-safety-issues-for-pregnant-women.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/legal/25/11/48902798/court-rejects-bid-to-block-kenvues-398-million-shareholder-payout-in-tylenol-safety-dispute","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/legal/25/11/48902798/court-rejects-bid-to-block-kenvues-398-million-shareholder-payout-in-tylenol-safety-dispute","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0289739699.SGD","IE00B19Z3581.USD","IE00B2B36J28.USD","LU0320765646.SGD","LU2750360997.AUD","IE00BLSP4452.SGD","LU1023059063.AUD","BK4592","LU2133065610.SGD","BK4533","LU0203347892.USD","LU0234570918.USD","BK4534","LU1066051225.USD","LU1674673428.USD","LU2112291526.USD","LU0070217475.USD","IE0002141913.USD","LU1674673691.USD","BK4567","IE0009355771.USD","JNJ","ADHD","LU0058720904.USD","KMB","IE00BVYPNV92.GBP","LU1074936037.SGD","BK4588","IE0002270589.USD","LU1066051498.USD","LU1496350502.SGD","LU2430703178.SGD","IE00BJT1NW94.SGD","LU2347655156.SGD","LU2505996509.AUD","LU2430703251.USD","IE00BFTCPJ56.SGD","LU1244550221.USD","LU0912757837.SGD","LU0122379950.USD","LU0466842654.USD","LU1221951129.SGD","BK4532","LU1506573853.SGD","LU1935042991.SGD","LU2592432038.USD","LU0889566641.SGD","BK4581","LU0792757196.USD","IE00BN8TJ469.HKD"],"gpt_icon":0},{"id":"2583655005","title":"Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2583655005","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583655005?lang=en_us&edition=fundamental","pubTime":"2025-11-16 00:25","pubTimestamp":1763223929,"startTime":"0","endTime":"0","summary":"Cingulate Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from Maxim Group reiterated a Bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cingulate-inc-s-promising-market-position-bolstered-by-strategic-partnerships-and-innovative-adhd-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cingulate-inc-s-promising-market-position-bolstered-by-strategic-partnerships-and-innovative-adhd-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4581","BK4007","BK4585","XBI","ABVC","ADHD","LABU","CING","XLV"],"gpt_icon":0},{"id":"2583258504","title":"Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258504","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583258504?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981500,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., Nov.  12, 2025  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186793/19871/en/Supernus-to-Participate-in-the-2025-Jefferies-Global-Healthcare-Conference-in-London.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","CNS","BK4023","BK4121","BK4581","XLV","LABU","LU0029874061.USD","BK4135","PD","LU0128526141.USD","BK4561","HCSG","BK4530","LU1169589451.USD","BK4137","PPD","LU1169590202.USD","ADHD","BK4588"],"gpt_icon":0},{"id":"2582879286","title":"Press Release: Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879286","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879286?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval. Company also strengthens its cash position by completing a $6 million financing. Cingulate also announced it has completed a $6 million financing transaction, further strengthening its balance sheet and extending its cash runway into the second quarter of 2026, as the company prepares for commercialization, subject to FDA approval.\"Cingulate is at a pivotal moment as we prepare to bring CTx-1301 to market,\" said Bryan Downey, Chief Commercial Officer. \"The potential to deliver rapid onset and entire active-day ADHD symptom control in one daily dose is a substantial differentiator from medications currently available. With our new drug application now accepted for review, we're working closely with our partners at Indegene to establish the commercial infrastructure, market access execution, and launch readiness that will positi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ","QID","PSQ","BK4007","QLD","TSYW.SI","ADHD","USJW.SI","MNQmain","03160","TQQQ",".IXIC","BK4099","BK4604","BK4585","CING","BK4555","BK4139","NVIW.SI","USAW.SI","NQmain","ABVC","BK4588","TM"],"gpt_icon":1},{"id":"2581696677","title":"Supernus Announces Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581696677","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581696677?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290060,"startTime":"0","endTime":"0","summary":"Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024. This strong growth was driven by an increase ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180807/19871/en/Supernus-Announces-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4121","BK4530","CNS","PD","LU1169590202.USD","LU1169589451.USD","BK4561","PPD","ADHD","BK4023"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}